The investigational new drug applications (INDs) signify the company’s intentions to begin clinical investigation for CB-182,804, a Cubist-discovered, potent, cidal, IV lipopeptide in development as therapy for the treatment of multi-drug resistant gram-negative infections, and CB-183,315, a Cubist-discovered, potent, oral, cidal lipopeptide in development for the treatment of Clostridium difficile associated diarrhea.
Mike Bonney, president and CEO of Cubist, said, “These INDs demonstrate our continued commitment to building a significant product pipeline in the acute care setting. I am particularly proud that both of these antibiotic candidates are based on discoveries by Cubist scientists.”